CDKN2A and cancer: Expression sites of these factors were largely overlapping with those of senescent cells (p16INK4a+ and p21CIP1) in the TME, excluding cancer cells, which may have survived and progressively repopulated after therapy (Figure 2g; Sun et al., 2012).